Tokyo, Japan and San Diego, U.S. - Tosoh Corporation and Gen-Probe announced today that the companies have cross-licensed intellectual property covering certain nucleic acid testing (NAT) technologies. The licenses, which are effective January 1, 2004, cover products in clinical diagnostics and other related fields.
Tosoh will receive non-exclusive rights to Gen-Probe's proprietary transcription-mediated amplification (TMA) and ribosomal RNA technologies in exchange for two payments in 2004. Additionally, Tosoh will pay Gen-Probe royalties on worldwide sales of products that employ the licensed Gen-Probe technologies.
Gen-Probe will gain access, in exchange for royalties, to Tosoh's patented TRC (Transcription reverse-transcription concerted) amplification and INAF (Intercalation activating fluorescence) detection technologies for use with real time TMA.
"The combination of proprietary technologies from Tosoh and Gen-Probe will further support our strategy of positioning Tosoh Bioscience in new emerging growth markets. We look forward to continuing our collaboration with Gen-Probe as Tosoh introduces more products in the future," said Madoka Tashiro, Chairman and CEO of Tosoh Corporation.
"This agreement with Tosoh enables us to realize additional value from our broad patented technologies, gain additional income from new market segments we are not currently targeting, and access additional innovative NAT technologies," said Henry L. Nordhoff, chairman, president and CEO of Gen-Probe.